Inquire Before Buying - GCC Geographical Atrophy Market Size, Trends & Forecast 2026-2032

GCC Geographical Atrophy Market Research Report: Trends, Forecast & Opportunities (2026-2032)

By Diagnosis Method (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)), By Age Group (Below 60 Years, Above 6......0 Years, Above 70 Years), By Therapeutic Agents (Late stage (Phase III), Phase II, Phase I, Pre-clinical & Discovery Candidates), By Therapy Type (Complement Inhibitors, Gene Therapy & Regenerative Approaches, Small Molecules & Others), By Drug Class (Anti-VEGF Agents, Complement Pathway Inhibitors, Cell and Gene Therapies, Other Therapeutics), By Route of Administration (Intravitreal, Oral, Others), By End User (Hospitals, Ophthalmic Clinics / Specialty Eye Care Centers, Homecare & Others), and others Read more

Healthcare
Mar 2026
Pages 290
Report Format: PDF, Excel, PPT

GCC Geographical Atrophy Market Report Key Takeaways:

The GCC Geographical Atrophy market size was valued at around USD 1.05 billion in 2025 and is projected to grow from USD 1.41 billion in 2026 to USD 5.01 billion by 2032, exhibiting a CAGR of 23.63% during the forecast period.
Saudi Arabia holds the largest market share of about 39% in the GCC Geographical Atrophy Market in 2026.
By diagnosis method, the optical coherence tomography angiography segment represented a significant share of about 40% in the GCC Geographical Atrophy Market in 2026.
By route of administration, the intravitreal segment seized a significant share of about 67% in the GCC Geographical Atrophy Market in 2026.
Leading geographical atrophy companies in the UAE Market are Apellis Pharmaceuticals, Iveric Bio (Astellas Pharma Inc.), Novartis AG, Roche Holding AG (Genentech, Inc.), Regenerative Patch Technologies LLC, Gyroscope Therapeutics Limited, Alkeus Pharmaceuticals, Inc., Stealth BioTherapeutics, Lineage Cell Therapeutics, Inc., Hemera Biosciences LLC, and Others.

Market Insights & Analysis: GCC Geographical Atrophy Market (2026-32):

The GCC Geographical Atrophy Market size was valued at around USD 1.05 billion in 2025 and is projected to grow from USD 1.41 billion in 2026 to USD 5.01 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 23.63% during the forecast period, i.e., 2026-32.

The GCC Geographic Atrophy (GA) Market is poised for substantial growth, driven primarily by the rising prevalence of age-related macular degeneration (AMD) among aging populations. AMD, a leading cause of vision loss and the precursor to GA, is increasingly diagnosed across the Gulf Cooperation Council countries due to longer life expectancies and changing demographics. Historical burden estimates highlight that countries such as Kuwait and Monaco report higher macular degeneration prevalence within the Eastern Mediterranean region, reflecting persistent patterns of age-related vision loss. As the population ages, the number of individuals at risk for GA rises, creating strong demand for early diagnosis and advanced therapeutic interventions .

A key trend shaping the market is the integration of artificial intelligence (AI) in ophthalmic diagnostics. AI-powered imaging systems enhance early detection and monitoring of GA and related retinal diseases by improving accuracy, speed, and consistency in interpreting complex retinal images. For instance, Medcare Hospital Al Safa in the UAE implemented the Airdoc AI retinal image interpretation system, capable of detecting over 35 retina-related conditions with reported accuracy exceeding 95% through high-resolution fundus analysis. This implementation has improved early screening efficiency and patient outcomes, demonstrating the transformative role of AI in retinal care .

Looking ahead, future investments in healthcare infrastructure and digital health capabilities are expected to accelerate market growth. Saudi Arabia and the UAE are projected to lead most of the nearly 92% of healthcare deals in the Gulf from 2021–2025. Strategic national initiatives, such as Saudi Vision 2030 and the UAE 2023–2026 Health Strategy, are designed to strengthen diagnostic, therapeutic, and innovation ecosystems, supporting the adoption of advanced GA treatments and promoting research in ophthalmic care . These initiatives include expanding specialized retinal clinics, integrating advanced imaging and AI technologies, and enhancing access to innovative therapies.

Overall, the GCC GA market is entering a period of dynamic growth, underpinned by demographic shifts, technological innovation, and strategic government investments. The combination of rising AMD prevalence, AI-driven diagnostic improvements, and strengthened healthcare infrastructure positions the region to meet growing patient demand, optimize treatment outcomes, and expand the adoption of advanced GA therapies in the coming years.

GCC Geographical Atrophy Market Recent Developments:

2025: Astellas Pharma showcased expanded real‑world and long‑term safety data for IZERVAY™ (avacincaptad pegol) at the American Academy of Ophthalmology Annual Meeting, supporting broader clinical understanding that could support future regulatory and payer interest worldwide, including GCC regions .

GCC Geographical Atrophy Market Scope:

Category	Segments
By Diagnosis Method	(Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)),
By Age Group	(Below 60 Years, Above 60 Years, Above 70 Years),
By Therapeutic Agents	(Late stage (Phase III), Phase II, Phase I, Pre-clinical & Discovery Candidates),
By Therapy Type	(Complement Inhibitors, Gene Therapy & Regenerative Approaches, Small Molecules & Others),
By Drug Class	(Anti-VEGF Agents, Complement Pathway Inhibitors, Cell and Gene Therapies, Other Therapeutics),
By Route of Administration	(Intravitreal, Oral, Others),
By End User	(Hospitals, Ophthalmic Clinics / Specialty Eye Care Centers, Homecare & Others),

GCC Geographical Atrophy Market Driver:

Rising Prevalence of Age-Related Macular Degeneration (AMD)

The increasing prevalence of age‑related macular degeneration (AMD), the primary precursor to geographic atrophy (GA), is a significant driver of the GCC market. Data from the Eastern Mediterranean Region (EMR), which includes the UAE, Saudi Arabia, Qatar, Kuwait, Oman, and Bahrain, indicate a substantial burden of AMD among older adults. For example, Oman recorded an age‑standardized AMD prevalence of approximately 239.7 cases per 100,000 . Saudi Arabia reported 229.5 cases per 100,000 in 2021, highlighting significant retinal disease prevalence within the aging population .

Clinical observations from Saudi ophthalmic centers further indicate that 4% of patients presenting to eye clinics are diagnosed with AMD, with prevalence rising sharply among individuals aged 65 and above. These statistics underscore the growing patient pool at risk for GA, which is further amplified by increasing life expectancy across GCC nations.

Looking beyond 2025, GCC governments are implementing strategic initiatives, including expanded geriatric eye health programs, nationwide retinal screening campaigns, and integration of advanced diagnostic tools such as optical coherence tomography (OCT) into routine clinical practice. These measures are expected to improve early detection, optimize treatment pathways, and enhance patient outcomes.

Overall, the escalating prevalence of AMD among aging GCC populations, supported by regional epidemiological and clinical evidence, is a key driver of market growth, fueling demand for advanced diagnostics and therapeutic interventions for geographic atrophy.

Market Segmentation
Introduction
1. Product Definition
2. Research Process
3. Assumptions
Executive Summary
GCC Geographical Atrophy Market Policies, Regulations, and Product Standards
GCC Geographical Atrophy Market Trends & Developments
GCC Geographical Atrophy Market Dynamics
1. Growth Factors
2. Challenges
GCC Geographical Atrophy Market Hotspot & Opportunities
GCC Geographical Atrophy Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
    1. Fundus Autofluorescence (FAF)
    2. Optical Coherence Tomography Angiography (OCT-A)
    3. Multifocal Electroretinography (mfERG)
  2. By Age Group- Market Size & Forecast 2022-2032, USD Million
    1. Below 60 Years
    2. Above 60 Years
    3. Above 70 Years
  3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
    1. Late stage (Phase III)
    2. Phase II
    3. Phase I
    4. Pre-clinical & Discovery Candidates
  4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
    1. Complement Inhibitors
    2. Gene Therapy & Regenerative Approaches
    3. Small Molecules & Others
  5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
    1. Anti-VEGF Agents
    2. Complement Pathway Inhibitors
    3. Cell and Gene Therapies
    4. Other Therapeutics
  6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
    1. Intravitreal
    2. Oral
    3. Others
  7. By End User- Market Size & Forecast 2022-2032, USD Million
    1. Hospitals
    2. Ophthalmic Clinics / Specialty Eye Care Centers
    3. Homecare & Others
  8. By Country
    1. The UAE
    2. Saudi Arabia
    3. Qatar
    4. Kuwait
    5. Oman
    6. Bahrain
    7. Rest of GCC
  9. By Company
    1. Competition Characteristics
    2. Market Share & Analysis
The UAE Geographical Atrophy Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
  2. By Age Group- Market Size & Forecast 2022-2032, USD Million
  3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
  4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
  5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
  6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  7. By End User- Market Size & Forecast 2022-2032, USD Million
Saudi Arabia Geographical Atrophy Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
  2. By Age Group- Market Size & Forecast 2022-2032, USD Million
  3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
  4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
  5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
  6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  7. By End User- Market Size & Forecast 2022-2032, USD Million
Qatar Geographical Atrophy Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
  2. By Age Group- Market Size & Forecast 2022-2032, USD Million
  3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
  4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
  5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
  6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  7. By End User- Market Size & Forecast 2022-2032, USD Million
Kuwait Geographical Atrophy Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
  2. By Age Group- Market Size & Forecast 2022-2032, USD Million
  3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
  4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
  5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
  6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  7. By End User- Market Size & Forecast 2022-2032, USD Million
Oman Geographical Atrophy Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
  2. By Age Group- Market Size & Forecast 2022-2032, USD Million
  3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
  4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
  5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
  6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  7. By End User- Market Size & Forecast 2022-2032, USD Million
Bahrain Geographical Atrophy Market Outlook, 2022-2032F
1. Market Size & Outlook
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Diagnosis Method- Market Size & Forecast 2022-2032, USD Million
  2. By Age Group- Market Size & Forecast 2022-2032, USD Million
  3. By Therapeutic Agents- Market Size & Forecast 2022-2032, USD Million
  4. By Therapy Type- Market Size & Forecast 2022-2032, USD Million
  5. By Drug Class- Market Size & Forecast 2022-2032, USD Million
  6. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
  7. By End User- Market Size & Forecast 2022-2032, USD Million
GCC Geographical Atrophy Market Key Strategic Imperatives for Success & Growth
Competitive Outlook
1. Company Profiles
  1. Apellis Pharmaceuticals
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  2. Iveric Bio (Astellas Pharma Inc.)
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  3. Novartis AG
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  4. Roche Holding AG (Genentech, Inc.)
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  5. Regenerative Patch Technologies LLC
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  6. Gyroscope Therapeutics Limited
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  7. Alkeus Pharmaceuticals, Inc.
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  8. Stealth BioTherapeutics
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  9. Lineage Cell Therapeutics, Inc.
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  10. Hemera Biosciences LLC
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
  11. Other
    1. Business Description
    2. Product Portfolio
    3. Collaborations & Alliances
    4. Recent Developments
    5. Financial Details
    6. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *